analysed in the subset of the ITT population who had measurable disease at
|Response rates were
significantly higher in both bevacizumab arms than the placebo arm, with 44%
in the placebo arm, 55% in the bevacizumab 7.5mg/kg arm and 63% in the
bevacizumab 15mg/kg arm.
|Although there is a
numerical difference between the two bevacizumab arms, this is not